An interesting finding......recently published in the British Journal of Urology International (Jan-12) re investigation into the "subtypes" of bladder cancer. See excerpts directly below. I found the growth trend of the two subtypes of definite interest. And, reporting research results by subtypes (article's recommendation) appears to relate back to how Endo/ Bioniche reported the results of Urocidin's phase III trials.
Article: "Bladder Cancer - Differentiate Between Types When Conducting Studies, Researchers Urged"
Excerpts:
When investigators examined the two main subtypes, which accounted for 94% of the bladder tumors, they discovered that between 1973 and 2007, papillary transitional cell carcinoma rose by 56% and that non-papillary transitional cell carcinoma decreased by 53%.
Dr. Yawei Zhang, from the of and of at , explained:
"These two subtypes of bladder cancer are normally categorized as a single disease called transitional cell carcinoma in research studies, but our findings highlight major trend differences over more than three decades.
This is a significant finding that underlines the importance of future researchdifferentiating between these two subtypes."
https://www.medicalnewstoday.com/articles/240027.php
And, recall the presentation of Urocidin's first phase III trials...
CHADDS FORD, PA, and BELLEVILLE, ON, May 17, 2011 - Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin™...
A total of 129 patients were enrolled from 25 centers in the and , with high grade papillary tumors and/or carcinoma in situ (CIS) and having failed to respond to one or more courses of BCG. According to the preliminary results the overall one-year disease-free survival (DFS) rate was 25 percent. DFS is defined as lack of recurrence or progression to muscle-invasive disease, as confirmed by biopsy. The one-yearDFS rate was35percentfor patients with onlypapillary tumors and 21 percent for patients with carcinoma in situ (CIS)with or without papillary tumors. The preliminary results indicate that intravesical administration of Urocidin™ was well tolerated.
So, not a perfect overlap if I understand correctly (papillary yes, CIS not quite due to above "with or without" papillary tumours) and Urocidin results for NMI bladder cancer only.
Nevertheless, the subtype of tumours that Urocidin performs best with (papillary tumours), is the growth area.
And, I assume this also helps to explain these figures... "Papillary tumours account for ~90%of NMIBC and CIS around 10%. Source: Taylor & Collison's March 24-11 report.
T&C also stated in their Mar 24-11 report, "The result (Urocidin's phIII trial results) gives us further confidence that Urocidin™will be initially indicated for both recurrent papillary and CIS."
Note: Endo's current bladder cancer treatment Valstar, is only approved for BCG refractory CIS tumours.
If interested (and have some time), you may also find the videos shown on Bladder Cancer 's website quite informative (link provided below) re "Patient Education Meeting". The first two videos provide a very good overview of bladder cancer. When watching, keep in mind reference to "cat type" = papillary tumours and "tigers/lions" = CIS tumours (if I understood correctly). You certainly will recognize the sponsor of the website. Hopefully link is live.... https://www.bladdercancercanada.org/main.php
Some extra time on my hands this morn. Cannot figure out why the sp is where it's at but continue to like all I come across regarding the potential for Urocidin, hence Bioniche. Have one more observation I will try to post later today. rg